JP2007504174A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504174A5
JP2007504174A5 JP2006525016A JP2006525016A JP2007504174A5 JP 2007504174 A5 JP2007504174 A5 JP 2007504174A5 JP 2006525016 A JP2006525016 A JP 2006525016A JP 2006525016 A JP2006525016 A JP 2006525016A JP 2007504174 A5 JP2007504174 A5 JP 2007504174A5
Authority
JP
Japan
Prior art keywords
disorders
epilepsy
pharmaceutical composition
pain
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006525016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504174A (ja
Filing date
Publication date
Priority claimed from US10/655,393 external-priority patent/US7186726B2/en
Application filed filed Critical
Publication of JP2007504174A publication Critical patent/JP2007504174A/ja
Publication of JP2007504174A5 publication Critical patent/JP2007504174A5/ja
Pending legal-status Critical Current

Links

JP2006525016A 2003-09-03 2004-09-03 カルシウムチャネル遮断薬として使用されるピペラジン置換化合物 Pending JP2007504174A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/655,393 US7186726B2 (en) 1998-06-30 2003-09-03 Preferentially substituted calcium channel blockers
PCT/CA2004/001629 WO2005021523A1 (en) 2003-09-03 2004-09-03 Piperazine substituted compounds used as calcium channel blockers

Publications (2)

Publication Number Publication Date
JP2007504174A JP2007504174A (ja) 2007-03-01
JP2007504174A5 true JP2007504174A5 (en:Method) 2007-10-18

Family

ID=34273458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525016A Pending JP2007504174A (ja) 2003-09-03 2004-09-03 カルシウムチャネル遮断薬として使用されるピペラジン置換化合物

Country Status (12)

Country Link
US (2) US7186726B2 (en:Method)
EP (1) EP1670775A4 (en:Method)
JP (1) JP2007504174A (en:Method)
CN (1) CN1871225A (en:Method)
AU (1) AU2004268711A1 (en:Method)
BR (1) BRPI0414094A (en:Method)
CA (1) CA2537487A1 (en:Method)
IL (1) IL174025A0 (en:Method)
MX (1) MXPA06002467A (en:Method)
NZ (1) NZ546254A (en:Method)
WO (1) WO2005021523A1 (en:Method)
ZA (1) ZA200602684B (en:Method)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US20040266784A1 (en) * 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US20060084660A1 (en) * 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US7186726B2 (en) * 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US20040259866A1 (en) * 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
KR20070044803A (ko) * 2004-04-09 2007-04-30 뉴로메드 파머큐티칼즈 리미티드 칼슘 채널 차단제로서 디아릴아민 유도체
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US7378420B2 (en) * 2004-08-30 2008-05-27 Neuromed Pharmaceuticals Ltd. Urea derivatives as calcium channel blockers
US7511077B2 (en) * 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
EP1871372A4 (en) * 2005-04-08 2010-06-02 Neuromed Pharmaceuticals Ltd COMBINATION THERAPY WHICH INCLUDES AN AGENT BLOCKING CALCIUM CHANNELS OF TYPE N FOR THE RELIEF OF PAIN
WO2006124865A2 (en) * 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryls derivatives useful as modulators of ion channels
WO2006130493A2 (en) 2005-05-31 2006-12-07 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
US20090221603A1 (en) * 2005-12-19 2009-09-03 Hassan Pajouhesh Heterocyclic amide derivatives as calcium channel blockers
CA2643924A1 (en) * 2006-04-17 2007-10-25 Neuromed Pharmaceuticals Ltd. Isoxazole derivatives as calcium channel blockers
US8362021B2 (en) * 2006-05-11 2013-01-29 Zalicus Pharmaceuticals Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
WO2007137417A1 (en) * 2006-05-26 2007-12-06 Neuromed Pharmaceuticals Ltd. Heterocyclic compounds as calcium channel blockers
WO2008031227A1 (en) * 2006-09-14 2008-03-20 Neuromed Pharmaceuticals Ltd. Diaryl piperidine compounds as calcium channel blockers
EP2074105A4 (en) * 2006-10-13 2010-10-06 Neuromed Pharmaceuticals Ltd CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM INHIBITORS
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
WO2008050200A1 (en) * 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
US20080139578A1 (en) * 2006-11-30 2008-06-12 Catherine Abbadie Substituted piperizines for the treatment of pain
GB0700893D0 (en) 2007-01-17 2007-02-21 King S College London Male contraceptive
KR101352709B1 (ko) 2007-05-22 2014-01-16 아스테라스 세이야쿠 가부시키가이샤 1위 치환 테트라히드로이소퀴놀린 화합물
MX2010004028A (es) * 2007-10-17 2010-04-30 Kudos Pharm Ltd 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
US20090270413A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Di-t-butylphenyl piperazines as calcium channel blockers
US20090270338A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Diaryl-cyclylalkyl derivatives as calcium channel blockers
PT2346495T (pt) 2008-10-07 2016-11-11 Astrazeneca Uk Ltd Formulação farmacêutica 514
EP3002008B8 (en) 2010-03-11 2018-10-24 New York University Amido compounds as roryt modulators and uses thereof
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
KR20140072090A (ko) 2011-09-09 2014-06-12 뉴욕 유니버시티 ＲＯＲγｔ 조정제로서의 아미도 화합물 및 이의 용도
CN103130745B (zh) * 2011-11-28 2017-03-15 中国人民解放军军事医学科学院毒物药物研究所 二芳基哌嗪类化合物及其医药用途
CN105218501A (zh) * 2014-07-03 2016-01-06 南京大学 含哌嗪环的香豆素类衍生物及其制备与在抗菌药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB920416A (en) 1958-04-04 1963-03-06 Lakeside Lab Inc Piperazino compounds
GB1051527A (en:Method) 1964-07-31
BG17385A1 (en:Method) 1971-11-09 1973-11-10
US3997539A (en) 1974-05-31 1976-12-14 American Hoechst Corporation 3-(4-Acylaminopiperazin-1-yl alkyl)indoles, precursors and processes for the preparation thereof
US4188485A (en) 1978-06-16 1980-02-12 G. D. Searle & Co. 1-[(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)methyl]-4-substituted piperidines and related compounds
ES8304135A3 (es) 1981-07-06 1983-01-01 Ferrer Int Procedimiento de obtencion de benzhidrilpiperazinas
ES514167A0 (es) 1982-07-20 1983-04-01 Ferrer Int "procedimiento de obtencion de benzhidrilpiperazinas".
JPS61155358A (ja) 1984-12-21 1986-07-15 Suntory Ltd ジアリール酪酸誘導体
FR2584723B1 (fr) 1985-07-09 1988-02-12 Adir Nouveaux derives du dihydro-2,3 benzofuranne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
DE3600390A1 (de) 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
US5386025A (en) 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
IE73232B1 (en) 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
US5703071A (en) 1990-08-29 1997-12-30 Pharmacia & Upjohn Company Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
TW205034B (en:Method) 1990-09-13 1993-05-01 Pola Kasei Kogyo Kk
ES2024991A6 (es) * 1990-12-27 1992-03-01 Uriach & Cia Sa J Procedimiento para la obtencion de piperazinilcarboxamidas.
ES2027897A6 (es) 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la difenilmetilpiperacina.
DE4111861A1 (de) 1991-04-11 1992-10-15 Schwabe Willmar Gmbh & Co Benzopyranone, verfahren zu ihrer herstellung und verwendung
WO1994014786A1 (en) 1992-12-22 1994-07-07 Smithkline Beecham Plc Piperidine derivatives as calcium channel antagonists
JP3204424B2 (ja) * 1993-02-18 2001-09-04 三菱化学フォームプラスティック株式会社 ポリプロピレン系樹脂発泡粒子
CA2153979C (en) 1993-12-08 2003-10-21 Mark Hellberg Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
US5623051A (en) 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
JPH10135749A (ja) * 1996-10-29 1998-05-22 Nec Corp 高周波帯増幅器
CA2234342A1 (en) 1997-04-10 1998-10-10 Kyowa Hakko Kogyo Co., Ltd. Pancreatitis remedy
IT1293804B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Diarilalchilpiperazine attive sulle basse vie urinarie
EP1140791A2 (en) 1997-09-23 2001-10-10 Bristol-Myers Squibb Company Selective cpla 2 inhibitors
NZ503782A (en) 1997-11-18 2002-03-28 Dupont Pharmaceuticals Res Lab Cyclic amine derivatives and chemokine receptor antagonists that are effective in treating disease caused by infiltration of the tissue by blood leukocytes
AU3459999A (en) 1998-04-27 1999-11-16 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
US6943168B2 (en) * 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US6387897B1 (en) 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US7186726B2 (en) 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6310059B1 (en) 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US6267945B1 (en) 1998-12-18 2001-07-31 Neuromed Technologies, Inc. Farnesol-related calcium channel blockers
WO2002053550A1 (en) * 2000-12-27 2002-07-11 Pola Chemical Industries, Inc. Benzofuran derivatives and pharmaceutical compositions containing the same
GB0203299D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel compounds
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.

Similar Documents

Publication Publication Date Title
JP2007504174A5 (en:Method)
JP2003503454A5 (en:Method)
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
NO20090095L (no) Anvendelse av en hydrofil matriks omfattende et polyakrylsyrederivat, en cellulose-eter og et disintegreringsmiddel for fremstilling av et medikament for behandling av kvinners genitale forstyrrelser
JP2010535252A5 (en:Method)
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
JP2009502743A5 (en:Method)
IL186303A (en) 1h - benzamideimzole - 4 carboxyamides converted with quarterly carbon in position 2, the pharmaceutical composition containing it and its use for the preparation of a drug @ for the treatment @ of cancer
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
CL2007003262A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
EP1979324A4 (en) IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE DISORDER, MORBUS ALZHEIMER, NEURODEGENERATION AND DEMENTIA.
JP2009500443A5 (en:Method)
JP2007514005A5 (en:Method)
JP2008534627A5 (en:Method)
IL189500A (en) 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p
EP3276004A3 (en) Methods for treating chronic kidney disease
JP2007536277A5 (en:Method)
JP2005507892A5 (en:Method)
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
JP2005509503A5 (en:Method)
SG137850A1 (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
WO2006113978A3 (en) Insulins combinations
JP2013537901A5 (en:Method)
ZA200405342B (en) The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus